Compounds > ag 1295

ag 1295 and semaxinib

ag 1295 has been researched along with semaxinib in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gangjee, A; Ihnat, MA; Namjoshi, OA; Thorpe, JE; Warnke, LA; Yu, J1
Cody, V; Gangjee, A; Green, DW; Ihnat, M; Li, W; Lin, L; Pace, J; Queener, SF; Warnke, LA; Zeng, Y1
Buchanan, A; Gangjee, A; Ihnat, MA; Namjoshi, OA1
Gangjee, A; Ihnat, MA; Raghavan, S; Thorpe, JE; Yang, J; Zaware, N1
Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Namjoshi, OA; Thorpe, JE; Yu, J1
Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A1

Other Studies

6 other study(ies) available for ag 1295 and semaxinib

ArticleYear
Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
    Bioorganic & medicinal chemistry, 2008, May-15, Volume: 16, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Sensitivity and Specificity; Stereoisomerism; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-1

2008
Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors.
    Bioorganic & medicinal chemistry, 2009, Oct-15, Volume: 17, Issue:20

    Topics: Animals; Chromatography, High Pressure Liquid; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Humans; Mice; Models, Molecular; Molecular Structure; Pyrimidines; Rats; Receptor Protein-Tyrosine Kinases; Tetrahydrofolate Dehydrogenase

2009
The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines.
    Bioorganic & medicinal chemistry letters, 2010, May-15, Volume: 20, Issue:10

    Topics: Angiogenesis Inhibitors; Catalytic Domain; Cell Line, Tumor; Computer Simulation; ErbB Receptors; Humans; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2

2010
N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.
    Bioorganic & medicinal chemistry, 2012, Apr-01, Volume: 20, Issue:7

    Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Design; Humans; Indoles; Mice; Mice, Nude; Molecular Dynamics Simulation; Neoplasms; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2

2012
N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastati
    Bioorganic & medicinal chemistry, 2013, Mar-01, Volume: 21, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Design; Humans; Melanoma, Experimental; Mice; Mice, Nude; Microwaves; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship

2013
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
    The Biochemical journal, 2013, Apr-15, Volume: 451, Issue:2

    Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase

2013